other disorders, but this expansion could be more limited than expected. Often there are many different mutations for a disease with anyone accounting for only a small percentage of cases, so it is impractical and expensive to test for most of them. (Cystic fibrosis is unusual in that only a few mutations out of the several hundred discovered account for most defective genes.) A test that measures an early biochemical or other manifestation of a "genetic" disease may be simpler, less expensive, and more effective at identifying those individuals who may, without treatment or intervention, develop the overt disease -for example, neonatal biochemical screening for phenylketonuria is simple and highly effective, so there is no advantage in replacing it with a genetic test. Measuring iron overload (transferrin saturation)in haemochromatosis may be better than testing for the mutation. A blood count (mean cell haemoglobin) is used to screen for thalassaemia, and the change in shape of red cells if the pH of their surrounding fluid changes is used to screen for sickle cell disease. A simple test for the disease phenotype may be more sensitive and specific than a test for the genotype. Screening methods for neural tube defects and Down's syndrome use biochemical markers, not genetic tests. An open mind is needed, and the choice of the type of test will vary according to the disease. Even if DNA screening tests become more common in the future, there is no need and no public advantage in declaring the technology used as the screening method of choice.
Another reason for avoiding the term "genetic screening" is that it may imply that geneticists should carry out screening that falls under this heading, as screening relies on "genetic" tests. The terminology should be neutral with respect to who does the screening; often screening for genetic disorders requires little specialist genetic expertise. Medical screening is better described in terms of the disease being screened for, as in cystic fibrosis screening, though sometimes an indication of the technology involved is helpful if there are alternative methods (for example, serum screening for Down's syndrome or ultrasound screening for Down's syndrome), but this is unnecessary when there is only one practical method available.
Describing medical screening in terms of the disease that screening is aimed at detecting or preventing not only avoids many of the problems associated with the term "genetic screening" but' also has the simple advantage that it focuses on the purpose of screening. In doing so, it keeps attention on the burden of morbidity and mortality from the disease in question, and the extent to which this can be reduced through screening. NJWALD Editor
